Indication & Dosage |
| |
| |
| Inhalation |
| INDUCTION AND MAINTENANCE OF GENERAL ANAESTHESIA |
| Adult:
Induction: 2-4% v/v of halothane in O2 or mixtures of nitrous oxide and O2. Alternatively, 0.5% v/v of halothane may be used for induction and gradually increased to the required level for maintenance of anaesthesia. Maintain anesthesia at 0.5-2% v/v depending on the flow rate used. |
| |
| Inhalation |
| INDUCTION AND MAINTENANCE OF GENERAL ANAESTHESIA |
| Child:
1.5-2% v/v. Maintenance of anaesthesia: 0.5-2% v/v depending on the flow rate used. |
|
| |
|
| Precautions |
Phaeochromocytoma; poor cardiac/liver function, early pregnancy. Premedication with atropine is recommended to decrease vagal tone and prevent bradycardia and severe hypotension. May trigger malignant hyperthermia and increase intracranial pressure. Increased risk of hyperkalaemia in paediatrics with underlying neuromuscular disorders. May reduce hepatic, renal and splenic blood flow. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Bradycardia, hypotension, cardiac arrhythmias, respiratory depression, shivering during recovery (occasional), hepatitis (multiple exposure). |
| |
|
| Adverse Drug Reactions |
Fulminant hepatic failure, malignant hyperpyrexia and pulmonary oedema. |
| |
|
| Interactions |
Adrenaline, other sympathomimetics, and theophylline can produce cardiac arrhythmias. Morphine and chlorpromazine may increase depressant effects of halothane on respiration. Increased risk of phenytoin intoxication when used together. Midazolam may potentiate the anaesthetic action of halothane. |
| |
|
